Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00086619 · ClinicalTrials.gov registry record · Phase 2

Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women

A Phase 2 study of Osteoporosis and Postmenopausal Osteoporosis, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 2
Development phase
80
Enrollment target
1
Study location

NCT00086619 is a Phase 2 study of Osteoporosis and Postmenopausal Osteoporosis that has completed, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00086619, a Phase 2 study of Osteoporosis and Postmenopausal Osteoporosis, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 2
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

Parathyroid hormone (PTH) increases bone formation and thereby improves bone density and bone strength in postmenopausal women with osteoporosis. However, prolonged PTH treatment increases bone formation less and less over time. This study will test whether increasing the daily dose of PTH sustains its ability to improve bone formation, and optional sub-studies will test several potential reasons why PTH's effects on bone formation decline over time.

Interventions

  • DRUG synthetic hPTH 1-34

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2004-05
Est. Completion 2009-12
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT00086619

The ClinicalTrials.gov registry entry for NCT00086619 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (95% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which synthetic hPTH 1-34 is the first listed.

NCT00086619 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00086619 about?

NCT00086619 is a clinical study titled "Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women". Parathyroid hormone (PTH) increases bone formation and thereby improves bone density and bone strength in postmenopausal women with osteoporosis. However, prolonged PTH treatment increases bone formation less and less over time. This study will test whether increasing the daily dose of PTH sustains ...

What is the current status of trial NCT00086619?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2004-05. Estimated completion is 2009-12.

What conditions does trial NCT00086619 study?

This clinical trial studies the following conditions: Osteoporosis, Postmenopausal Osteoporosis.

What interventions are being tested in trial NCT00086619?

The interventions under investigation include: synthetic hPTH 1-34 (DRUG).

Who is sponsoring clinical trial NCT00086619?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00086619 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoporosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.